R.K. Jongensschool St. Jozef in Besoijen. Achterste rij van links naar rechts: van Delft (leraar), NN, Schapendonk, NN, NN, Pelgzin, NN, Tinus Mahieu, Passier, Koos van Os. 2e rij van achter: Bruurmijn, Verhagen, Henkelman (met das), Bruurmijn. De andere namen zijn onbekend
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale.
Autorzy:
Otto ME; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.; Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands. Bergmann KR; Centre for Human Drug Research (CHDR), Leiden, The Netherlands. de Kam ML; Centre for Human Drug Research (CHDR), Leiden, The Netherlands. Recourt K; Centre for Human Drug Research (CHDR), Leiden, The Netherlands. JacobsGE; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.; Department of Psychiatry, Leiden University Medical Center (LUMC), Leiden, The Netherlands. van Esdonk MJ; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
Autorzy:
Recourt K; Centre for Human Drug Research, Leiden, the Netherlands. .; Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands. . de Boer P; Janssen Research and Development, a Division of Janssen Pharmaceutica N.V, Beerse, Belgium. van der Ark P; Janssen Research and Development, a Division of Janssen Pharmaceutica N.V, Beerse, Belgium. Benes H; Janssen Research and Development, a Division of Janssen Pharmaceutica N.V, Beerse, Belgium. van Gerven JMA; Centre for Human Drug Research, Leiden, the Netherlands.; Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands. Ceusters M; Janssen Research and Development, a Division of Janssen Pharmaceutica N.V, Beerse, Belgium. van Nueten L; Janssen Research and Development, a Division of Janssen Pharmaceutica N.V, Beerse, Belgium. Drevets WC; Janssen Research and Development LLC, La Jolla, CA, USA. Bhatacharya A; Janssen Research and Development LLC, La Jolla, CA, USA. Browning M; University of Oxford, Oxford, UK.; Oxford Health NHS Trust, Oxford, UK. JacobsGE; Centre for Human Drug Research, Leiden, the Netherlands.; Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands.
Pokaż więcej
Źródło:
Translational psychiatry [Transl Psychiatry] 2023 Jul 24; Vol. 13 (1), pp. 266. Date of Electronic Publication: 2023 Jul 24.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants.
Autorzy:
Cholewinski T; Centre for Human Drug Research, Leiden, The Netherlands. Pereira D; Centre for Human Drug Research, Leiden, The Netherlands. Moerland M; Centre for Human Drug Research, Leiden, The Netherlands. JacobsGE; Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The Netherlands.
Pokaż więcej
Źródło:
Therapeutic advances in psychopharmacology [Ther Adv Psychopharmacol] 2021 Oct 28; Vol. 11, pp. 20451253211036814. Date of Electronic Publication: 2021 Oct 28 (Print Publication: 2021).
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation.
Autorzy:
O'Donnell P; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA. .; McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, USA. . Dijkstra FM; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.; Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands. Damar U; Neuromodulation Program, Department of Neurology and F.M. Kirby Center for Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Quanhong L; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA. de Goede AA; Centre for Human Drug Research (CHDR), Leiden, The Netherlands. Xu L; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA. Pascual-Leone A; Neuromodulation Program, Department of Neurology and F.M. Kirby Center for Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Buhl DL; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA. Zuiker R; Centre for Human Drug Research (CHDR), Leiden, The Netherlands. Ruijs TQ; Centre for Human Drug Research (CHDR), Leiden, The Netherlands. Heuberger JAAC; Centre for Human Drug Research (CHDR), Leiden, The Netherlands. MacMullin P; Neuromodulation Program, Department of Neurology and F.M. Kirby Center for Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Lubell M; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA. Asgharnejad M; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA. Murthy V; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA. Rotenberg A; Neuromodulation Program, Department of Neurology and F.M. Kirby Center for Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. JacobsGE; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.; Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands. Rosen L; Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA.
Pokaż więcej
Źródło:
Translational psychiatry [Transl Psychiatry] 2021 May 27; Vol. 11 (1), pp. 325. Date of Electronic Publication: 2021 May 27.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.
Autorzy:
Sverdlov O; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Curcic J; Novartis Institutes for Biomedical Research, Basel, Switzerland. Hannesdottir K; Novartis Institutes for Biomedical Research, Cambridge, MA, United States. Gou L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. De Luca V; Novartis Institutes for Biomedical Research, Basel, Switzerland. Ambrosetti F; Novartis Institutes for Biomedical Research, Basel, Switzerland. Zhang B; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC, United States. Praestgaard J; Novartis Institutes for Biomedical Research, Cambridge, MA, United States. Vallejo V; Novartis Institutes for Biomedical Research, Basel, Switzerland. Dolman A; Novartis Institutes for Biomedical Research, Cambridge, MA, United States. Gomez-Mancilla B; Novartis Institutes for Biomedical Research, Basel, Switzerland. Biliouris K; Novartis Institutes for Biomedical Research, Cambridge, MA, United States. Deurinck M; Novartis Institutes for Biomedical Research, Basel, Switzerland. Cormack F; Cambridge Cognition, Cambridge, United Kingdom. Anderson JJ; Neurotrack Technologies, Inc., Redwood City, CA, United States. Bott NT; Department of Medicine, School of Medicine, Stanford University, Stanford, CA, United States. Peremen Z; ElMindA Ltd., Herzliya, Israel. Issachar G; ElMindA Ltd., Herzliya, Israel. Laufer O; ElMindA Ltd., Herzliya, Israel. Joachim D; Sonde Health, Inc., Boston, MA, United States. Jagesar RR; Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands. Jongs N; Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands. Kas MJ; Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands. Zhuparris A; Centre for Human Drug Research, Leiden, Netherlands. Zuiker R; Centre for Human Drug Research, Leiden, Netherlands. Recourt K; Centre for Human Drug Research, Leiden, Netherlands. Zuilhof Z; Centre for Human Drug Research, Leiden, Netherlands. Cha JH; Novartis Institutes for Biomedical Research, Cambridge, MA, United States. JacobsGE; Centre for Human Drug Research, Leiden, Netherlands.; Department of Psychiatry, Leiden University Medical Center, Leiden, Netherlands.
Pokaż więcej
Źródło:
Frontiers in psychiatry [Front Psychiatry] 2021 May 06; Vol. 12, pp. 640741. Date of Electronic Publication: 2021 May 06 (Print Publication: 2021).
Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?
Autorzy:
Drukarch B; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, the Netherlands. Electronic address: . JacobsGE; Centre for Human Drug Research, Leiden, the Netherlands; Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands. Wilhelmus MMM; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, the Netherlands.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies